Inhibition of experimental angiogenesis of cornea by somatostatin

Pei Chang Wu; Chi Chang Liu; Chih Hsin Chen; Hsi Kung Kou; Su Chin Shen; Cheng Yuan Lu; Wen Ying Chou; Ming Tse Sung; Lin Cheng Yang

doi:10.1007/s00417-002-0591-7

Inhibition of experimental angiogenesis of cornea by somatostatin

Pei Chang Wu
, Chi Chang Liu
, Chih Hsin Chen
, Hsi Kung Kou
, Su Chin Shen
, Cheng Yuan Lu
, Wen Ying Chou
, Ming Tse Sung
, Lin Cheng Yang^*

^*Corresponding author for this work

Chang Gung Memorial Hospital

Research output: Contribution to journal › Journal Article › peer-review

38 Scopus citations

Abstract

Background: This study evaluated the inhibitory activity of somatostatin 14 on the angiogenesis of cornea in vivo. Methods: Corneal neovascularization was induced with a pellet containing 90 ng of basic fibroblast growth factor (bFGF) in a rat corneal pocket model. Three kinds of pellets were made containing bFGF plus somatostatin (SST) 0 ng, 20 ng and 200 ng for the control group, group 1 and group 2, respectively. Neovascularization was observed biomicroscopically from day 4 to day 8, and the corneas were then examined for changes in histology. Quantitation of angiogenesis in the cornea was accomplished by caliper and image analysis. Results: The 200-ng dose of SST showed significant inhibition of both length and area of neovascularization on day 7 (0.62±0.11 mm vs 1.29±0.16 mm, 0.50±0.16 mm² vs 1.35±0.29mm², group 2 vs control; P <0.05). The 20 ng of somatostatin did not demonstrate any significant inhibition of neovascularization compared with the control group. Conclusion: Our study demonstrated that SST 14 can reduce bFGF-induced corneal angiogenesis. This shows the potential value of somatostatin in the treatment of corneal neovascularization.

Original language	English
Pages (from-to)	63-69
Number of pages	7
Journal	Graefe's Archive for Clinical and Experimental Ophthalmology
Volume	241
Issue number	1
DOIs	https://doi.org/10.1007/s00417-002-0591-7
State	Published - 01 01 2003
Externally published	Yes

Access to Document

10.1007/s00417-002-0591-7

Cite this

@article{2a20780c72754af9b9b109ecce2de5a3,

title = "Inhibition of experimental angiogenesis of cornea by somatostatin",

abstract = "Background: This study evaluated the inhibitory activity of somatostatin 14 on the angiogenesis of cornea in vivo. Methods: Corneal neovascularization was induced with a pellet containing 90 ng of basic fibroblast growth factor (bFGF) in a rat corneal pocket model. Three kinds of pellets were made containing bFGF plus somatostatin (SST) 0 ng, 20 ng and 200 ng for the control group, group 1 and group 2, respectively. Neovascularization was observed biomicroscopically from day 4 to day 8, and the corneas were then examined for changes in histology. Quantitation of angiogenesis in the cornea was accomplished by caliper and image analysis. Results: The 200-ng dose of SST showed significant inhibition of both length and area of neovascularization on day 7 (0.62±0.11 mm vs 1.29±0.16 mm, 0.50±0.16 mm2 vs 1.35±0.29mm2, group 2 vs control; P <0.05). The 20 ng of somatostatin did not demonstrate any significant inhibition of neovascularization compared with the control group. Conclusion: Our study demonstrated that SST 14 can reduce bFGF-induced corneal angiogenesis. This shows the potential value of somatostatin in the treatment of corneal neovascularization.",

author = "Wu, \{Pei Chang\} and Liu, \{Chi Chang\} and Chen, \{Chih Hsin\} and Kou, \{Hsi Kung\} and Shen, \{Su Chin\} and Lu, \{Cheng Yuan\} and Chou, \{Wen Ying\} and Sung, \{Ming Tse\} and Yang, \{Lin Cheng\}",

year = "2003",

month = jan,

day = "1",

doi = "10.1007/s00417-002-0591-7",

language = "英语",

volume = "241",

pages = "63--69",

journal = "Graefe's Archive for Clinical and Experimental Ophthalmology",

issn = "0721-832X",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Inhibition of experimental angiogenesis of cornea by somatostatin

AU - Wu, Pei Chang

AU - Liu, Chi Chang

AU - Chen, Chih Hsin

AU - Kou, Hsi Kung

AU - Shen, Su Chin

AU - Lu, Cheng Yuan

AU - Chou, Wen Ying

AU - Sung, Ming Tse

AU - Yang, Lin Cheng

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Background: This study evaluated the inhibitory activity of somatostatin 14 on the angiogenesis of cornea in vivo. Methods: Corneal neovascularization was induced with a pellet containing 90 ng of basic fibroblast growth factor (bFGF) in a rat corneal pocket model. Three kinds of pellets were made containing bFGF plus somatostatin (SST) 0 ng, 20 ng and 200 ng for the control group, group 1 and group 2, respectively. Neovascularization was observed biomicroscopically from day 4 to day 8, and the corneas were then examined for changes in histology. Quantitation of angiogenesis in the cornea was accomplished by caliper and image analysis. Results: The 200-ng dose of SST showed significant inhibition of both length and area of neovascularization on day 7 (0.62±0.11 mm vs 1.29±0.16 mm, 0.50±0.16 mm2 vs 1.35±0.29mm2, group 2 vs control; P <0.05). The 20 ng of somatostatin did not demonstrate any significant inhibition of neovascularization compared with the control group. Conclusion: Our study demonstrated that SST 14 can reduce bFGF-induced corneal angiogenesis. This shows the potential value of somatostatin in the treatment of corneal neovascularization.

AB - Background: This study evaluated the inhibitory activity of somatostatin 14 on the angiogenesis of cornea in vivo. Methods: Corneal neovascularization was induced with a pellet containing 90 ng of basic fibroblast growth factor (bFGF) in a rat corneal pocket model. Three kinds of pellets were made containing bFGF plus somatostatin (SST) 0 ng, 20 ng and 200 ng for the control group, group 1 and group 2, respectively. Neovascularization was observed biomicroscopically from day 4 to day 8, and the corneas were then examined for changes in histology. Quantitation of angiogenesis in the cornea was accomplished by caliper and image analysis. Results: The 200-ng dose of SST showed significant inhibition of both length and area of neovascularization on day 7 (0.62±0.11 mm vs 1.29±0.16 mm, 0.50±0.16 mm2 vs 1.35±0.29mm2, group 2 vs control; P <0.05). The 20 ng of somatostatin did not demonstrate any significant inhibition of neovascularization compared with the control group. Conclusion: Our study demonstrated that SST 14 can reduce bFGF-induced corneal angiogenesis. This shows the potential value of somatostatin in the treatment of corneal neovascularization.

UR - https://www.scopus.com/pages/publications/0037266592

U2 - 10.1007/s00417-002-0591-7

DO - 10.1007/s00417-002-0591-7

M3 - 文章

C2 - 12545294

AN - SCOPUS:0037266592

SN - 0721-832X

VL - 241

SP - 63

EP - 69

JO - Graefe's Archive for Clinical and Experimental Ophthalmology

JF - Graefe's Archive for Clinical and Experimental Ophthalmology

IS - 1

ER -

Inhibition of experimental angiogenesis of cornea by somatostatin

Abstract

Access to Document

Other files and links

Fingerprint

Cite this